These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24210757)

  • 1. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
    Dias MV; Tyrakis P; Domingues RR; Paes Leme AF; Blundell TL
    Structure; 2014 Jan; 22(1):94-103. PubMed ID: 24210757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
    Cheng YS; Sacchettini JC
    Biochemistry; 2016 Feb; 55(7):1107-19. PubMed ID: 26848874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of the closed form of Mycobacterium tuberculosis dihydrofolate reductase in complex with dihydrofolate and antifolates.
    Ribeiro JA; Chavez-Pacheco SM; de Oliveira GS; Silva CDS; Giudice JHP; Libreros-Zúñiga GA; Dias MVB
    Acta Crystallogr D Struct Biol; 2019 Jul; 75(Pt 7):682-693. PubMed ID: 31282477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased substrate affinity in the Escherichia coli L28R dihydrofolate reductase mutant causes trimethoprim resistance.
    Abdizadeh H; Tamer YT; Acar O; Toprak E; Atilgan AR; Atilgan C
    Phys Chem Chem Phys; 2017 May; 19(18):11416-11428. PubMed ID: 28422217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
    da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
    J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
    da Cunha EF; Ramalho TC; Reynolds RC
    J Biomol Struct Dyn; 2008 Feb; 25(4):377-85. PubMed ID: 18092832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
    Kumar M; Vijayakrishnan R; Subba Rao G
    Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
    Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
    Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trypanosomal dihydrofolate reductase reveals natural antifolate resistance.
    Vanichtanankul J; Taweechai S; Yuvaniyama J; Vilaivan T; Chitnumsub P; Kamchonwongpaisan S; Yuthavong Y
    ACS Chem Biol; 2011 Sep; 6(9):905-11. PubMed ID: 21650210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli.
    Tahar R; de Pécoulas PE; Basco LK; Chiadmi M; Mazabraud A
    Mol Biochem Parasitol; 2001 Apr; 113(2):241-9. PubMed ID: 11295178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of Klebsiella pneumoniae dihydrofolate reductase bound to propargyl-linked antifolates reveal features for potency and selectivity.
    Lamb KM; Lombardo MN; Alverson J; Priestley ND; Wright DL; Anderson AC
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7484-91. PubMed ID: 25288083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
    Senkovich O; Schormann N; Chattopadhyay D
    Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases--inhibition by folic acid and polyphenols.
    Kao TT; Wang KC; Chang WN; Lin CY; Chen BH; Wu HL; Shi GY; Tsai JN; Fu TF
    Drug Metab Dispos; 2008 Mar; 36(3):508-16. PubMed ID: 18056255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim.
    Raju A; Kulkarni S; Ray MK; Rajan MG; Degani MS
    Int J Mycobacteriol; 2015 Jun; 4(2):97-103. PubMed ID: 26972877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stoichiometric selection of tight-binding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase.
    Kamchonwongpaisan S; Vanichtanankul J; Tarnchompoo B; Yuvaniyama J; Taweechai S; Yuthavong Y
    Anal Chem; 2005 Mar; 77(5):1222-7. PubMed ID: 15732900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
    Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
    J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
    Bastien D; Ebert MC; Forge D; Toulouse J; Kadnikova N; Perron F; Mayence A; Huang TL; Vanden Eynde JJ; Pelletier JN
    J Med Chem; 2012 Apr; 55(7):3182-92. PubMed ID: 22424148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
    Adane L; Bharatam PV
    J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.